Biochanin A and its possible involvement in Parkinson’s disease management
Parkinson’s disease is typified by Lewy bodies and the selective death of dopaminergic neurons in the substantia nigra. α-Synuclein aggregation, neuroinflammation, mitochondrial dysfunction, and oxidative stress are key components of its pathophysiology. The neuroprotective potential of natural subs...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Open Exploration Publishing Inc.
2025-07-01
|
| Series: | Exploration of Neuroscience |
| Subjects: | |
| Online Access: | https://www.explorationpub.com/uploads/Article/A100698/100698.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849704114027495424 |
|---|---|
| author | Amninder Kaur Simran Kaur Amir Mushtaq Diksha Dalal Shubham Kumar Anish Singh |
| author_facet | Amninder Kaur Simran Kaur Amir Mushtaq Diksha Dalal Shubham Kumar Anish Singh |
| author_sort | Amninder Kaur |
| collection | DOAJ |
| description | Parkinson’s disease is typified by Lewy bodies and the selective death of dopaminergic neurons in the substantia nigra. α-Synuclein aggregation, neuroinflammation, mitochondrial dysfunction, and oxidative stress are key components of its pathophysiology. The neuroprotective potential of natural substances with anti-inflammatory and antioxidant qualities has drawn attention in recent years. A naturally occurring isoflavone that is mostly present in red clover and other legumes, biochanin A has shown promise as a treatment option for Parkinson’s disease. Preclinical research has shown that biochanin A uses a variety of methods to provide notable neuroprotective benefits. By activating the Nrf2/ARE pathway, it scavenges reactive oxygen species (ROS), upregulates antioxidant defense enzymes, and inhibits pro-inflammatory mediators by modifying the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling cascade. Additionally, it has been demonstrated that biochanin A preserves neuronal integrity in Parkinson’s disease models by reducing dopaminergic neuronal death, inhibiting microglial activation, and mitigating mitochondrial dysfunction. Its potential as a neurotherapeutic agent is increased by its capacity to pass the blood-brain barrier. To investigate its safety, bioavailability, and effectiveness in people, more translational and clinical research is necessary. Biochanin A’s incorporation with neuroprotective techniques may pave the way for novel supplementary treatments for Parkinson’s disease. Therefore, the current review aims to present a thorough investigation of the molecular basis of biochanin A’s anti-Parkinson properties in Parkinson’s disease, building on the body of existing research that explains these properties. |
| format | Article |
| id | doaj-art-56e71fca810e44aa9688a2fd2885b0fc |
| institution | DOAJ |
| issn | 2834-5347 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Open Exploration Publishing Inc. |
| record_format | Article |
| series | Exploration of Neuroscience |
| spelling | doaj-art-56e71fca810e44aa9688a2fd2885b0fc2025-08-20T03:16:52ZengOpen Exploration Publishing Inc.Exploration of Neuroscience2834-53472025-07-01410069810.37349/en.2025.100698Biochanin A and its possible involvement in Parkinson’s disease managementAmninder Kaur0Simran Kaur1Amir Mushtaq2Diksha Dalal3https://orcid.org/0000-0003-1707-6135Shubham Kumar4Anish Singh5https://orcid.org/0000-0002-8547-2263School of Pharmacy, Desh Bhagat University, Mandigobindgarh 147301, Punjab, IndiaSchool of Pharmacy, Desh Bhagat University, Mandigobindgarh 147301, Punjab, IndiaSchool of Pharmacy, Desh Bhagat University, Mandigobindgarh 147301, Punjab, IndiaSchool of Pharmacy, Desh Bhagat University, Mandigobindgarh 147301, Punjab, IndiaUniversity Institute of Pharma Sciences, Chandigarh University, Mohali 140413, Punjab, IndiaSchool of Pharmacy, Desh Bhagat University, Mandigobindgarh 147301, Punjab, IndiaParkinson’s disease is typified by Lewy bodies and the selective death of dopaminergic neurons in the substantia nigra. α-Synuclein aggregation, neuroinflammation, mitochondrial dysfunction, and oxidative stress are key components of its pathophysiology. The neuroprotective potential of natural substances with anti-inflammatory and antioxidant qualities has drawn attention in recent years. A naturally occurring isoflavone that is mostly present in red clover and other legumes, biochanin A has shown promise as a treatment option for Parkinson’s disease. Preclinical research has shown that biochanin A uses a variety of methods to provide notable neuroprotective benefits. By activating the Nrf2/ARE pathway, it scavenges reactive oxygen species (ROS), upregulates antioxidant defense enzymes, and inhibits pro-inflammatory mediators by modifying the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling cascade. Additionally, it has been demonstrated that biochanin A preserves neuronal integrity in Parkinson’s disease models by reducing dopaminergic neuronal death, inhibiting microglial activation, and mitigating mitochondrial dysfunction. Its potential as a neurotherapeutic agent is increased by its capacity to pass the blood-brain barrier. To investigate its safety, bioavailability, and effectiveness in people, more translational and clinical research is necessary. Biochanin A’s incorporation with neuroprotective techniques may pave the way for novel supplementary treatments for Parkinson’s disease. Therefore, the current review aims to present a thorough investigation of the molecular basis of biochanin A’s anti-Parkinson properties in Parkinson’s disease, building on the body of existing research that explains these properties.https://www.explorationpub.com/uploads/Article/A100698/100698.pdfparkinson’s diseasebiochanin aisoflavonesdopaminergic neuronsnuclear factor kappa-light-chain-enhancer of activated b cells (nf-κb)reactive oxygen species (ros) |
| spellingShingle | Amninder Kaur Simran Kaur Amir Mushtaq Diksha Dalal Shubham Kumar Anish Singh Biochanin A and its possible involvement in Parkinson’s disease management Exploration of Neuroscience parkinson’s disease biochanin a isoflavones dopaminergic neurons nuclear factor kappa-light-chain-enhancer of activated b cells (nf-κb) reactive oxygen species (ros) |
| title | Biochanin A and its possible involvement in Parkinson’s disease management |
| title_full | Biochanin A and its possible involvement in Parkinson’s disease management |
| title_fullStr | Biochanin A and its possible involvement in Parkinson’s disease management |
| title_full_unstemmed | Biochanin A and its possible involvement in Parkinson’s disease management |
| title_short | Biochanin A and its possible involvement in Parkinson’s disease management |
| title_sort | biochanin a and its possible involvement in parkinson s disease management |
| topic | parkinson’s disease biochanin a isoflavones dopaminergic neurons nuclear factor kappa-light-chain-enhancer of activated b cells (nf-κb) reactive oxygen species (ros) |
| url | https://www.explorationpub.com/uploads/Article/A100698/100698.pdf |
| work_keys_str_mv | AT amninderkaur biochaninaanditspossibleinvolvementinparkinsonsdiseasemanagement AT simrankaur biochaninaanditspossibleinvolvementinparkinsonsdiseasemanagement AT amirmushtaq biochaninaanditspossibleinvolvementinparkinsonsdiseasemanagement AT dikshadalal biochaninaanditspossibleinvolvementinparkinsonsdiseasemanagement AT shubhamkumar biochaninaanditspossibleinvolvementinparkinsonsdiseasemanagement AT anishsingh biochaninaanditspossibleinvolvementinparkinsonsdiseasemanagement |